PH12021552903A1 - Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof - Google Patents

Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Info

Publication number
PH12021552903A1
PH12021552903A1 PH1/2021/552903A PH12021552903A PH12021552903A1 PH 12021552903 A1 PH12021552903 A1 PH 12021552903A1 PH 12021552903 A PH12021552903 A PH 12021552903A PH 12021552903 A1 PH12021552903 A1 PH 12021552903A1
Authority
PH
Philippines
Prior art keywords
pcrv
antibodies
bind
methods
compositions
Prior art date
Application number
PH1/2021/552903A
Other languages
English (en)
Inventor
Alida Coppi
Christos Kyratsous
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12021552903A1 publication Critical patent/PH12021552903A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2021/552903A 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof PH12021552903A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11
PCT/US2020/037008 WO2020252029A1 (en) 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12021552903A1 true PH12021552903A1 (en) 2022-04-04

Family

ID=71948699

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552903A PH12021552903A1 (en) 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Country Status (17)

Country Link
US (3) US11655286B2 (cg-RX-API-DMAC7.html)
EP (1) EP3983015A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022536469A (cg-RX-API-DMAC7.html)
KR (1) KR20220019755A (cg-RX-API-DMAC7.html)
CN (1) CN113966343A (cg-RX-API-DMAC7.html)
AU (1) AU2020292283A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140075A1 (cg-RX-API-DMAC7.html)
CL (4) CL2021003215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015254A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192810A1 (cg-RX-API-DMAC7.html)
IL (1) IL288727A (cg-RX-API-DMAC7.html)
MA (2) MA54975B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021015156A (cg-RX-API-DMAC7.html)
PH (1) PH12021552903A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112462RA (cg-RX-API-DMAC7.html)
WO (1) WO2020252029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
EP4735478A1 (en) 2023-06-28 2026-05-06 Universität zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
CN118530352B (zh) * 2024-05-11 2025-03-25 重庆原伦生物科技有限公司 一种特异性识别铜绿假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4355786B2 (ja) 2001-01-26 2009-11-04 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスv抗原を用いる免疫化のための方法および組成物
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
SG186017A1 (en) * 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2248826B1 (en) 2008-01-10 2013-06-12 Shionogi&Co., Ltd. Antibody directed against pcrv
ES2370148T3 (es) 2008-01-11 2011-12-13 Eli Lilly & Company (e)-n-{3-[fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-ciclohepten-5-iliden)-propil]-fenil}-metilsulfonamida como modulador del receptor de glucocorticoides para el tratamiento de artritis reumatoide.
WO2010104052A1 (ja) * 2009-03-11 2010-09-16 塩野義製薬株式会社 抗緑膿菌作用を有するヒト化PcrV抗体
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2013070615A1 (en) * 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US20150284450A1 (en) * 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
HK1257193A1 (zh) * 2015-11-30 2019-10-18 Medimmune Limited 用於预防或治疗医源性肺炎的方法
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos

Also Published As

Publication number Publication date
MA56205A (fr) 2022-04-20
MA54975A1 (fr) 2022-05-31
BR112021023335A2 (pt) 2022-01-04
US12552856B2 (en) 2026-02-17
CA3140075A1 (en) 2020-12-17
CL2023003696A1 (es) 2024-06-14
US20260184768A1 (en) 2026-07-02
EA202192810A1 (ru) 2022-03-05
SG11202112462RA (en) 2021-12-30
JP2022536469A (ja) 2022-08-17
MX2021015156A (es) 2022-01-18
EP3983015A1 (en) 2022-04-20
US20200392210A1 (en) 2020-12-17
AU2020292283A1 (en) 2021-12-23
WO2020252029A1 (en) 2020-12-17
CL2023003694A1 (es) 2024-06-14
US11655286B2 (en) 2023-05-23
CO2021015254A2 (es) 2021-11-19
CL2021003215A1 (es) 2022-09-30
KR20220019755A (ko) 2022-02-17
CL2023003695A1 (es) 2024-06-14
MA54975B1 (fr) 2023-08-31
CN113966343A (zh) 2022-01-21
IL288727A (en) 2022-02-01
US20230322907A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
WO2018234793A3 (en) Antibodies
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2017220989A8 (en) ANTI-PD-L1 AND CYTOKINES IL-2
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
WO2020257289A3 (en) Humanized antibody molecules to cd138 and uses thereof
AU2018279184A1 (en) Anti-TrkB antibodies
WO2019202399A8 (en) Antibodies for chelated radionuclides and clearing agents
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
ZA202006216B (en) Antibodies targeting glycoprotein vi
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.
MY208387A (en) Antibodies specifically recognizing pseudomonas pcrv and uses thereof
WO2020191181A9 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof
WO2020257633A3 (en) Monoclonal antibodies against jc virus